Abstract:Objective: To detect the expression of miR-221/222 in serum and plasma cells in patients with monoclonal gammopathy of undetermined significance(MGUS) and multiple myeloma(MM), and to explore the possibility of miR-221/222 as biomarkers in the diagnosis and prognosis predicting of MGUS and MM. Methods: Bone marrow and serum samples from 14 patients with newly diagnosed MGUS, 81 patients with newly diagnosed or relapsed MM and 10 controls were collected from Sir Run Run Shaw Hospital of Zhejiang University and Tongde Hospital of Zhejiang Province during January 2013 and December 2015. The expressions of miR-221/222 in serum and in sorted CD138 positive plasma cells were detected by qRT-PCR, and the relative expression of miR-221/222 (Δct) was compared between the groups. Serum levels of miR-221 before and after treatment were compared in both remission group (n=22) and refractory group (n=13) in MM patients, and its correlation with serum level of β2-MG was assessed using Pearson's correlation analysis. Results: Serum levels of miR-221/222 in MGUS and MM groups were significantly higher than those in control group (all P<0.01), while miR-221/222 levels in plasma cells were significantly lower in MGUS and MM groups than those in the control group (P<0.05 or<0.01). No significant difference in miR-221/222 levels in serum and plasma cells was observed between MGUS group and MM group (all P>0.05). There was no correlation between miR-221/222 levels in serum and plasma cells (r=0.024 and -0.127, all P>0.05), but miR-221 levels were correlated with miR-222 levels in both serum and plasma cells (r=0.534 and 0.552, all P<0.01). Receiver operating characteristic (ROC) curves showed that the areas under the curve (AUCs) of serum miR-221/222, plasma cell miR-221/222 in diagnosis of MGUS/MM were 0.968, 0.976, 0.801 and 0.727, respectively. There was no significant difference in serum level of miR-221 among MM patients with different paraprotein isotypes (P>0.05), but serum level of miR-221 in patients with relapsed MM was higher than that in patients with newly diagnosed MM (P<0.01). Compared with the patients with MGUS or MM stageⅠ and Ⅱ, patients with MM stage Ⅲ were of higher serum levels of miR-221 (P<0.01). Serum level of miR-221 decreased after chemotherapy in the remission group (U=51.5, P<0.01), but such decrease was not observed in the refractory group (U=67.5, P>0.05). Serum level of β2-MG was positively correlated with serum level of miR-221 (r=0.524, P<0.01). Conclusion: miR-221/222 in serum and plasma cells may be biomarkers for early diagnosis of MGUS, and are helpful for diagnosis and efficacy evaluation of MM.

Potential Value of Mir-221/222 As Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases

Molecular Mechanisms and Clinical Applications of Mir-22 in Regulating Malignant Progression in Human Cancer (Review)

[Expression of Microrna-221/222 in Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma].

MicroRNAs As Potential Biomarkers in Cancer: Opportunities and Challenges

Circulating microRNAs: Biomarkers of disease

Prognostic Value of miR-222 in Various Cancers: a Systematic Review and Meta-Analysis.

Advances of miR-221/222 in tumors

Functions and Underlying Mechanisms of Mir-650 in Human Cancers

miR-26a is a Key Therapeutic Target with Enormous Potential in the Diagnosis and Prognosis of Human Disease

Role of miR-221/222 in Tumor Development and the Underlying Mechanism.

MicroRNA-Based Diagnosis and Therapy

The Role of Mirna-223 in Cancer: Function, Diagnosis and Therapy

MicroRNA-224: As a Potential Target for Mir-Based Therapy of Cancer.

The Potential Role of miR-451 in Cancer Diagnosis, Prognosis, and Therapy

miRNA-based biomarkers, therapies, and resistance in Cancer

Dysregulation of Mir-411 in Cancer: Causative Factor for Pathogenesis, Diagnosis and Prognosis.

Sensing Mirnas for Disease Diagnostics

MicroRNA-based Therapeutic Technologies

Role and mechanism of miR-211 in human cancer

MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis